亚马逊巴西交互流行:既往登革感染与COVID-19风险升高的队列研究
在巴西亚马逊地区一项基于人群的队列研究中,2019年登革病毒IgG阳性率为37.0%,2020年SARS-CoV-2 IgG阳性率为35.2%。
要点
- 既往登革感染未显示对SARS-CoV-2的交叉保护,反而与临床显性COVID-19风险加倍相关。
- 队列中2020年SARS-CoV-2抗体阳性者57.1%报告有临床表现。
- 60岁以上人群出现症状性COVID-19的可能性是5岁以下儿童的两倍。
核心结论
- 既往登革感染与SARS-CoV-2感染后临床显性COVID-19风险增加两倍相关,不支持交叉保护假说。
研究设计与样本
- 基于巴西亚马逊地区人群的队列研究,纳入1285名参与者,随访13个月,使用混合效应多重 logistic 回归分析。
主要发现
- 2019年登革IgG阳性率为37.0%(95%CI 34.3%-39.7%),随访期间血清转化率为10.4/100人年(95%CI 6.7-15.5)。
- 2020年SARS-CoV-2 IgG阳性率为35.2%(95%CI 32.6%-37.8%),448名血清阳性者中57.1%(95%CI 52.4%-61.8%)报告感染时有临床表现。
- 年龄>60岁者出现症状性COVID-19的可能性是<5岁儿童的两倍。
- 当地SARS-CoV-2分离株属于B.1.1.33谱系。
临床怎么用
- 在登革和SARS-CoV-2序贯流行的社区,应关注既往登革感染者可能面临更高的临床显性COVID-19风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunity after dengue virus (DENV) infection has been suggested to cross-protect from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and mortality. METHODS: We tested whether serologically proven prior DENV infection diagnosed in September-October 2019, before the coronavirus disease 2019 (COVID-19) pandemic, reduced the risk of SARS-CoV-2 infection and clinically apparent COVID-19 over the next 13 months in a population-based cohort in Amazonian Brazil. Mixed-effects multiple logistic regression analysis was used to identify predictors of infection and disease, adjusting for potential individual and household-level confounders. Virus genomes from 14 local SARS-CoV-2 isolates were obtained using whole-genome sequencing. RESULTS: Anti-DENV immunoglobulin G (IgG) was found in 37.0% of 1285 cohort participants (95% confidence interval [CI]: 34.3% to 39.7%) in 2019, with 10.4 (95% CI: 6.7-15.5) seroconversion events per 100 person-years during the follow-up. In 2020, 35.2% of the participants (95% CI: 32.6% to 37.8%) had anti-SARS-CoV-2 IgG and 57.1% of the 448 SARS-CoV-2 seropositives (95% CI: 52.4% to 61.8%) reported clinical manifestations at the time of infection. Participants aged >60 years were twice more likely to have symptomatic COVID-19 than children under 5 years. Locally circulating SARS-CoV-2 isolates were assigned to the B.1.1.33 lineage. Contrary to the cross-protection hypothesis, prior DENV infection was associated with twice the risk of clinically apparent COVID-19 upon SARS-CoV-2 infection, with P values between .025 and .039 after adjustment for identified confounders. CONCLUSIONS: Higher risk of clinically apparent COVID-19 among individuals with prior dengue has important public health implications for communities sequentially exposed to DENV and SARS-CoV-2 epidemics.
引用
- Nicolete VC, Rodrigues PT, Johansen IC, et al. Interacting Epidemics in Amazonian Brazil: Prior Dengue Infection Associated With Increased Coronavirus Disease 2019 (COVID-19) Risk in a Population-Based Cohort Study. Clin Infect Dis. 2021. PMID: 33956939. doi:10.1093/cid/ciab410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。